FDA Halts Clinical Trials for EZH2 Inhibitor After Patient Developed Secondary Cancer

Following a safety report of a pediatric patient who developed a secondary lymphoma, the FDA issued a partial clinical hold affecting new enrollment of patients with genetically defined solid tumors and hematologic malignancies,